塞德斯医疗在欧洲过敏与临床免疫学学会年会上,公布了其靶向药物Barzolvolimab的长期随访结果。数据显示,该药物在治疗停止后,仍能持续改善慢性自发性荨麻疹患者的血管性水肿症状,展现了持久的疗效潜力。这一积极发现,为患者提供了新的治疗希望,并可能重塑该领域的治疗格局。
塞德斯医疗在欧洲过敏与临床免疫学学会年会上,公布了其靶向药物Barzolvolimab的长期随访结果。数据显示,该药物在治疗停止后,仍能持续改善慢性自发性荨麻疹患者的血管性水肿症状,展现了持久的疗效潜力。这一积极发现,为患者提供了新的治疗希望,并可能重塑该领域的治疗格局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.